1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A

Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A

SSZSE:002793
4.31
CNY
+0.13
(+3.11%)
-0.23EPS
4.18BMarket Cap
Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A
SZSE:002793
(Shenzhen Stock Exchange)

Recent

price

4.31

P/E

ratio

- -

div

yld

0.89%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.27
1.87
1.85
2.1
2.29
2.05
2.44
5.82
7.06
4.18
4.47
2.52
2.18
2.48
2.14
2.12
Revenue per Share
0.17
0.21
0.18
0.25
0.32
0.32
0.34
0.48
0.59
0.22
0.28
-0.86
-0.61
-0.91
-0.27
-0.23
Basic EPS, GAAP
- -
- -
0.18
-0.05
0.06
0.01
-0.17
-0.42
-0.43
-0.27
-0.13
-0.8
0.21
-0.26
0.21
- -
Free Cash Flow per Basic Share
0.14
0.03
0.01
0.01
0.24
0.01
0.18
0.12
0.06
0.09
0.09
0.1
0.07
0.06
0.05
0.04
Dividend per Share
0.81
0.81
0.99
1.24
1.33
2.05
2.22
8.78
10.23
2.76
3
2.92
2.27
1.27
1.07
1.04
Book Value per Share
0.78
0.51
0.69
0.95
1.05
1.83
1.66
7.96
8.78
2.34
2.54
2.32
1.62
0.65
0.52
0.5
Tangible Book Value per Share
187
253
256
256
255
310
340
1,067
1,074
1,458
1,450
1,424
1,084
1,066
1,062
1,081
Basic Weighted Avg Shares
423
475
474
537
584
637
828
6,211
7,589
6,096
6,478
3,588
2,364
2,647
2,273
2,292
Sales/Revenue/Turnover
11.32
13.47
13.46
15.8
16.9
15.73
17.64
8.66
10.62
9.04
10.52
-39.38
-14.48
-13.98
-6.23
-3.24
Operating Margin (%)
- -
- -
8
8
10
15
21
124
155
171
200
231
208
206
206
- -
Depreciation Expense
33
54
46
64
82
100
116
512
634
321
406
-1,225
-661
-965
-289
-250
Net Income, GAAP
21.12
14.58
13.33
13.76
13.54
13.58
13.26
8.02
9.73
16.29
13.1
- -
- -
- -
- -
- -
Effective Tax Rate (%)
7.68
11.31
9.69
11.9
14
15.75
13.99
8.25
8.35
5.26
6.27
-34.14
-27.97
-36.47
-12.69
-10.89
Profit Margin (%)
84
65
100
133
106
415
337
1,225
1,923
1,905
2,361
347
150
-754
-369
-489
Working Capital
- -
- -
- -
18
- -
- -
- -
- -
464
365
624
254
468
167
102
8
LT Debt
152
206
251
315
339
698
754
3,196
3,962
4,353
4,736
3,307
2,572
1,459
1,236
1,203
Total Equity
- -
22.96
16.2
19.38
20
17.3
15.94
21.72
14.02
6.34
6.17
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
24.68
17.51
21.05
21.47
17.96
16.04
22.73
14.78
6.2
7.18
- -
- -
- -
- -
- -
Return on Capital (%)
- -
30.03
20.11
22.56
24.97
19.34
15.95
27.4
19.02
8.31
9.64
-32.41
-23.42
-50.13
-22.67
-19.79
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
949
1,183
1,270
LT Borrowings
92
- -
- -
LT Finance Leases
10
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,088
1,088
1,088
Market Capitalization
5,220
5,307
4,176

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,929
1,756
1,853
Cash, Cash Equivalents & STI
554
806
983
Accounts Receivable, Net
429
323
256
Inventories
324
347
366
Total Current Liabilities
2,298
2,308
2,341
Payables & Accruals
- -
- -
- -
ST Debt
949
1,183
1,270
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.91%
-20.44%
-15.33%
Free Cash Flow
-283.47%
-14.52%
-180.85%
Net Income, GAAP
-9.04%
-89.02%
-70.11%
Sales/Revenue/Turnover
61.7%
-14.92%
-14.12%
Total Cash Common Dividend
238.14%
-16.6%
-19.95%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
689
571
622
766
2,647
2025
483
595
- -
550
2,273
2026
583
565
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.05
-0.17
-0.65
-0.91
2025
0.01
0.01
- -
-0.29
-0.27
2026
0.02
0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.06
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.01
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Luoxin Pharmaceuticals Group Stock Co., Ltd. stands as a comprehensive pharmaceutical entity dedicated to the research, development, production, and commercialization of medicinal products within China. The company’s extensive portfolio encompasses a variety of therapeutic areas, including innovative treatments for oncology, respiratory and gastrointestinal conditions, endocrine and cardiovascular ailments, nervous system disorders, and anti-infective agents. Beyond drug manufacturing, the enterprise also extends its operations to include medical treatment and broader health services. With a strategic emphasis on scientific and technological advancements, Luoxin maintains a robust research and development framework, actively pursuing innovative drug development. Recent initiatives include a private placement to bolster capital for ongoing projects and an organizational restructuring aimed at transitioning towards innovative drug solutions. The company has also engaged in various partnerships and licensing agreements to expand its product offerings and market reach. Established in 1998, the firm has consistently been recognized among China's top pharmaceutical companies for its R&D capabilities and overall industry influence. Headquartered in Linyi, China, the company's shares are traded on the Shenzhen Stock Exchange.